Evecxia Therapeutics
Latest round
- Series A
Last raised
- Sep 2025
Total raised
- $4.6M
Investors
- 1
About Evecxia Therapeutics
Evecxia, Inc. is a biopharmaceutical company focused on developing innovative drug delivery technologies to enhance serotonin production, targeting mental health conditions with unmet treatment needs. Founded in 2013 in the United States, Evecxia, Inc. specializes in therapeutic drugs aimed at increasing serotonin levels in the brain. In September 2025, Evecxia Therapeutics, Inc.Evecxia Therapeutics focuses on developing proprietary drug delivery technologies that leverage the therapeutic potential of 5-hydroxytryptophan (5-HTP), the natural precursor to serotonin. Their core product offerings aim to enhance serotonin production in the brain, targeting mental illnesses that are inadequately addressed by existing treatments. Evecxia's drugs are designed as adjunctive therapies for patients suffering from depression, particularly for those who do not achieve sufficient relief from standard antidepressants like SSRIs and SNRIs. The company's innovations are indicative of a shift towards more effective treatment options in mental health care, with a particular emphasis on improving patient outcomes in diverse demographics, including various age groups facing mental health challenges.Evecxia Therapeutics operates on a business model centered around partnerships and direct-to-consumer engagements, facilitating access to their innovative 5-HTP-based therapeutics. Their revenue structure includes sales through healthcare providers, pharmacies, and potentially digital health platforms, catering directly to patients who require adjunctive treatments for mental health conditions. While specific pricing plans for their products are not publicly disclosed, the company’s offerings are expected to be strategically positioned within the healthcare market to ensure accessibility and affordability for end-users.Evecxia, Inc. plans to expand its product line, focusing on new therapeutics designed to enhance serotonin levels, with anticipated market entry following regulatory approvals. In September 2025, Evecxia, Inc.
Who invested in Evecxia Therapeutics
1 investor across 1 round
See all investors in Evecxia Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 15, 2025
Amount
$4.6M
Investors
Questions about Evecxia Therapeutics
Who invested in Evecxia Therapeutics?
Evecxia Therapeutics has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Evecxia Therapeutics raised?
Evecxia Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Evecxia Therapeutics last raise money?
Evecxia Therapeutics's most recent round on record is a Series A, in Sep 2025.
What does Evecxia Therapeutics do?
Evecxia Therapeutics is a pharmaceuticals company.
Where is Evecxia Therapeutics headquartered?
Evecxia Therapeutics is headquartered in US.
Which VCs invest in companies like Evecxia Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Evecxia Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Evecxia Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.